NICE to review anti-TNF decision in RA

NICE has announced that it will review its decision to restrict the use of anti-TNF drugs for patients with rheumatoid arthritis (RA).

Credit: JH Lancy
Credit: JH Lancy

The U-turn comes after NICE announced last year that people with severe RA would not be permitted to try a second anti-TNF drug.

The decision resulted in an appeal by the Arthritis and Musculoskeletal Alliance (ARMA), the umbrella group for the charity Arthritis Care.

Rachel Haynes, director of public affairs at Arthritis Care, said: ‘We hope that NICE will put the needs of people above costs and reach the right conclusion quickly.

‘Not prescribing these life-transforming drugs to their full potential is like inventing the wheel but not using it because it is cheaper to walk.’

sanjay.tanday@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus